Summary: The exact identity of castrate-resistant (CR) cells and their relation to CR prostate cancer (CRPC) is unresolved. We use single-cell gene profiling to analyze the molecular heterogeneity in basal and luminal compartments. Within the luminal compartment, we identify a subset of cells intrinsically resistant to castration with a bi-lineage gene expression pattern. We discover LY6D as a marker of CR prostate progenitors with multipotent differentiation and enriched organoid-forming capacity. Lineage tracing further reveals that LY6D+ CR luminal cells can produce LY6D− luminal cells. In contrast, in luminal cells lacking PTEN, LY6D+ cells predominantly give rise to LY6D+ tumor cells, contributing to high-grade PIN lesions. Gene expres...
International audienceBACKGROUND: Cancer/Testis (CT) genes are expressed in male gonads, repressed i...
The identification of tumor-initiating cells represents a significant challenge for studies of prost...
Castration is the standard therapy for advanced prostate cancer (PC). Although this treatment is ini...
The prostate is a luminal secretory tissue whose function is regulated by male sex hormones. Castrat...
BACKGROUND: Prostate cancer is the second most frequent cancer among males worldwide, and most patie...
<div><p>New therapies for late stage and castration resistant prostate cancer (CRPC) depend on defin...
Androgen-dependent ("AD") early prostate cancer often switches to a lethal, castration-resistant (CR...
Prostate cancer is the most commonly diagnosed male malignancy. Despite compelling epidemiology, the...
SummaryPrimary prostate cancer almost always has a luminal phenotype. However, little is known about...
In this study, we extracted prostate cell-specific gene sets (metagenes) to define the epithelial di...
New therapies for late stage and castration resistant prostate cancer (CRPC) depend on defining uniq...
Item does not contain fulltextBACKGROUND: Castration-resistant prostate cancer (CRPC) represents a t...
The cell of origin for prostate cancer remains a subject of debate. Genetically engineered mouse mod...
Primary prostate cancer almost always has a luminal phenotype. However, little is known about the st...
The human prostate is a significant source of disease burden for adult males. In the malignant conte...
International audienceBACKGROUND: Cancer/Testis (CT) genes are expressed in male gonads, repressed i...
The identification of tumor-initiating cells represents a significant challenge for studies of prost...
Castration is the standard therapy for advanced prostate cancer (PC). Although this treatment is ini...
The prostate is a luminal secretory tissue whose function is regulated by male sex hormones. Castrat...
BACKGROUND: Prostate cancer is the second most frequent cancer among males worldwide, and most patie...
<div><p>New therapies for late stage and castration resistant prostate cancer (CRPC) depend on defin...
Androgen-dependent ("AD") early prostate cancer often switches to a lethal, castration-resistant (CR...
Prostate cancer is the most commonly diagnosed male malignancy. Despite compelling epidemiology, the...
SummaryPrimary prostate cancer almost always has a luminal phenotype. However, little is known about...
In this study, we extracted prostate cell-specific gene sets (metagenes) to define the epithelial di...
New therapies for late stage and castration resistant prostate cancer (CRPC) depend on defining uniq...
Item does not contain fulltextBACKGROUND: Castration-resistant prostate cancer (CRPC) represents a t...
The cell of origin for prostate cancer remains a subject of debate. Genetically engineered mouse mod...
Primary prostate cancer almost always has a luminal phenotype. However, little is known about the st...
The human prostate is a significant source of disease burden for adult males. In the malignant conte...
International audienceBACKGROUND: Cancer/Testis (CT) genes are expressed in male gonads, repressed i...
The identification of tumor-initiating cells represents a significant challenge for studies of prost...
Castration is the standard therapy for advanced prostate cancer (PC). Although this treatment is ini...